Laboratorios Farmaceuticos Rovi revenue and financials
€57.05Change from previous close: −0.61%Absolute change: −€0.35
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 743 | 764 | 830 | 818 | — |
| Cost of revenue | 261 | 285 | 337 | 298 | — |
| Gross profit | 483 | 478 | 492 | 520 | — |
| Selling, general and administrative | 36.0 | 39.4 | 38.0 | 32.8 | — |
| Operating income | 186 | 180 | 220 | 256 | — |
| EBIT | 186 | 180 | 221 | 259 | — |
| EBITDA | 216 | 208 | 245 | 281 | — |
| Interest expense | 2.6 | 2.0 | 0.7 | 0.6 | — |
| Pre-tax income | 183 | 178 | 220 | 258 | — |
| Income tax | 42.9 | 40.8 | 50.1 | 58.3 | — |
| Net income | 140 | 137 | 170 | 200 | — |
| Net income to common shareholders | 140 | 137 | 170 | 200 | — |
| Basic EPS | 2.75 | 2.68 | 3.29 | 3.73 | — |
| Diluted EPS | 2.75 | 2.68 | 3.29 | 3.73 | — |
| Average shares (basic) | 51.1 | 51.1 | 51.8 | 53.5 | — |
| Average shares (diluted) | 51.1 | 51.1 | 51.8 | 53.5 | — |